Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta‐analysis
Head & neck, 2013•Wiley Online Library
Background Human papillomavirus (HPV) positivity improves prognosis in patients with
oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other
biomarkers may improve its prognostic power. Methods The approach was a literature
search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta‐
analysis. Results In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion
criteria. On meta‐analysis, there was a significant overall survival (OS) benefit for patients …
oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other
biomarkers may improve its prognostic power. Methods The approach was a literature
search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta‐
analysis. Results In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion
criteria. On meta‐analysis, there was a significant overall survival (OS) benefit for patients …
Background
Human papillomavirus (HPV) positivity improves prognosis in patients with oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other biomarkers may improve its prognostic power.
Methods
The approach was a literature search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta‐analysis.
Results
In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion criteria. On meta‐analysis, there was a significant overall survival (OS) benefit for patients with HPV positive and p16 positive tumors. There was some evidence of improved OS of OPSCC patients with raised bcl2; amplification of 11q3 and loss of 16q genes; and low c‐met, ki67, IMD, PLK, FHIT, nuclear surviving, or nuclear cyclin D1. However, none of these was suitable for meta‐analysis.
Conclusion
Survival from OPSCC is associated with several biomarkers, which constitute potential targets for research into improving the prognostic power of HPV in OPSCC. Larger trials are needed, with standardization of cut‐points and adherence to consensus reporting guidelines. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果